Form 4 for MDCX Medicus Pharma Ltd.
Accepted 2026-09-08 17:02:20 ET · period of report 2026-09-04 · accession 0000950142-26-002522 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-08 17:02 | 2026-09-04 | MDCX | Smith Andrew Alasdair | COO | A - Grant | $0.1705 | +735.3K | 735.5K | +448,350% | +$125.4K |
| D | 2026-09-08 17:02 | 2026-09-04 | MDCX | Smith Andrew Alasdair | COO | A - Grant | $0.00 | +125.0K | 125.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares, no par value | 2026-09-04 | A | A | 735,294 | $0.1705 | 735,458 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2026-09-04 | A | A | 125,000 | $0.00 | 125,000 | D | $0.1705 · — to 2031-09-04 | 125,000 Common Shares | (F1) The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |